Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ligand Pharm (LGND)

144.4   2.69 (1.9%) 03-07 04:09
Open: 141.36 Pre. Close: 141.71
High: 147.16 Low: 135.48
Volume: 360,236 Market Cap: 2,399M
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 147.229 - 148.118 148.118 - 148.97
Low: 133.506 - 134.488 134.488 - 135.43
Close: 142.812 - 144.338 144.338 - 145.801

Technical analysis

as of: 2021-03-05 5:10:17 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 217.07     One year: 256.67
Support: Support1: 131.01    Support2: 109.00
Resistance: Resistance1: 185.85    Resistance2: 219.75
Pivot: 149.28
Moving Average: MA(5): 148.66     MA(20): 162.86
MA(100): 116.04     MA(250): 107.75
MACD: MACD(12,26): -2.20     Signal(9):
Stochastic oscillator: %K(14,3): 19.19     %D(3): 20.74
RSI: RSI(14): 44.58
52-week: High: 219.75  Low: 57.24  Change(%): 52.6
Average Vol(K): 3-Month: 65129  10-Days: 34242

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
LGND has closed above bottom band by 35.4%. Bollinger Bands are 12.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 05 Mar 2021
Ligand Pharmaceuticals Incorporated (LGND) Soars 1.9% on March 05 - Equities.com

Fri, 05 Mar 2021
Why Is Ligand (LGND) Down 21.3% Since Last Earnings Report? - Yahoo Finance

Tue, 02 Mar 2021
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Sees Significant Decrease in Short Interest - MarketBeat

Mon, 01 Mar 2021
Ligand Pharmaceuticals Incorporated (LGND) Soars 5.6% on March 01 - Equities.com

Fri, 26 Feb 2021
Ligand Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold - Investor's Business Daily

Tue, 16 Feb 2021
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expected to Post Quarterly Sales of $65.35 Million - MarketBeat

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 16
Shares Float (M) 15
% Held by Insiders 4.21
% Held by Institutions 146.13
Shares Short (K) 10,010
Shares Short P. Month (K) 9,980

Stock Financials

EPS -0.990
EPS Est This Year 2.950
EPS Est Next Year 3.870
Book Value (p.s.) 43.370
Profit Margin -11.23
Operating Margin 4.99
Return on Assets (ttm) 0.3
Return on Equity (ttm) -2.1
Qtrly Rev. Growth 68.7
Gross Profit (p.s.) 3.296
Sales Per Share 8.914
EBITDA (p.s.) 2.588
Qtrly Earnings Growth
Operating Cash Flow (M) 47
Levered Free Cash Flow (M) 47

Stock Valuations

PE Ratio -145.86
PEG Ratio
Price to Book value 3.33
Price to Sales 16.20
Price to Cash Flow 49.74

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date 2010-07-01
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.